Efficacy, Durability, and Safety of VYC ‐17. 5L Hyaluronic Acid Dermal Filler for Facial Enhancement: A Systematic Review and Single‐Arm Meta‐Analysis

ABSTRACT Background Facial aesthetics encompasses a variety of techniques to revitalize the face through aesthetic medicine. Satisfaction with one's face is important to well‐being, leading people to seek to maintain their youthful appearance throughout their lives. Accordingly, many techniques have been developed for facial rejuvenation. VYC‐17.5L (Volift/Vollure) is a hyaluronic acid–based dermal filler utilized for facial enhancement; however, evidence regarding its long‐term efficacy and safety remains inconsistent. Methods Following PRISMA guidelines, a systematic search was performed across PubMed, Scopus, Web of Science, ScienceDirect, Embase via Ovid, and Cochrane Library to identify studies evaluating VYC‐17.5L (Volift/Vollure) hyaluronic acid dermal fillers for facial aesthetic enhancement. Eligible studies included randomized controlled trials, prospective cohort studies, retrospective observational studies, and case series with ≥ 10 patients. Risk of bias was assessed using the Cochrane RoB 2 tool for randomized studies and ROBINS‐I for non‐randomized studies. Single‐arm meta‐analysis was performed to evaluate aesthetic outcomes (GAIS, FACE‐Q, NLFSS, WSRS, and responder rates) and safety outcomes. Results Eleven studies comprising 967 participants were included. Clinician‐assessed GAIS demonstrated a time‐dependent decline, reaching its peak at 3 months (87%–90%) and decreasing to (24%–33%) at 12 months. Patient‐reported GAIS responder rates remained high through 6 months (85%–95%) but declined to 62% at 9 months and 53% at 12 months. FACE‐Q responder rates remained high across the available 12‐month follow‐up. NLFSS responder rates remained consistently high (≥ 89%) up to 6 months, indicating sustained improvement in nasolabial fold severity. Adverse events were predominantly mild and transient; clinician‐reported frequencies were low, whereas patient‐reported frequencies were considerably higher. Conclusion VYC‐17.5L demonstrates favorable short‐term efficacy and safety for facial rejuvenation, with high patient satisfaction. Objective aesthetic improvements decline over time, highlighting the time‐limited nature of treatment effects and the importance of appropriate patient counseling. Trial Registration: PROSPERO number: CRD420261279046